Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This case report describes a 36-year-old Pakistani phenotypic female diagnosed with 46,XY 5-alpha-reductase deficiency, highlighting that such disorders of sexual development can manifest with symptoms like obesity, hirsutism, and amenorrhea later in life due to unique circumstances.

This article presents a case of 5-alpha-reductase deficiency in a Saudi individual, reporting no new research findings.

In this study, females with 5 alpha-reductase-2 deficiency exhibited decreased body hair, normal sebum production, and delayed menarche, suggesting a role for DHT in hair growth and menstrual function.

In this study, children with 5-alpha-reductase deficiency and micropenis treated with oral testosterone undecanoate showed increased penile length to a target level after 3-9 months, with no severe adverse effects observed, suggesting the treatment's safety and efficacy.

This review discusses the role of DHT in male sexual differentiation and fertility in individuals with 5α-reductase-2 deficiency, reporting no new clinical results.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.

This study details the isolation and characterization of the human type II 5 alpha-reductase gene, which may play a role in male pseudohermaphroditism, prostate cancer, and benign prostatic hyperplasia.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This chapter reviews recent advances in 5α-reductase inhibitors for treating disorders mediated by dihydrotestosterone and reports no new clinical findings.

This study identified multiple mutations in the 5 alpha-reductase-2 gene among male pseudohermaphrodites in the Dominican Republic, suggesting they do not share a common ancestry.

In this study, finasteride treatment for 56 days in adult rats led to sloughing of immature germinal cells and reduced sperm content in the epididymis, indicating its importance for maintaining spermatogenesis.

This study observed improvements in hair loss, acne, and BPH symptoms after addressing vitamin D and progesterone deficiencies in male patients, suggesting the potential benefits of this therapeutic approach.

This article discusses the structure of the human type II 5 alpha-reductase gene and reports no new experimental results.

In this study, researchers using QM/MM simulations identified key molecular motions and residue interactions in the enzyme SRD5A2 that significantly influence its catalytic efficiency, demonstrating that specific residues play critical roles in stabilizing transition states and reducing activation barriers.

This study found that intracrine androgen signaling via 5α-reductase is essential for optimal endometrial decidualization and vascular development during this process in mice.

This study found that intracrine androgen signaling, mediated by steroid 5α-reductase, is essential for optimal decidualization and vascular development in the endometrium during pregnancy, indicating potential targets for improving age-related fertility issues.

This review discusses the production, role, and measurement of dihydrotestosterone (DHT) in various disorders of sexual development but does not report new clinical results.

In this study, researchers used the FAERS database to identify rare adverse events potentially linked to spironolactone, finding new safety signals such as a possible association with male endometriosis, suggesting further research is needed to understand these findings better.

This article discusses the teratogenic risks of skin condition treatments for individuals with DSD and notes that testosterone replacement, often used in this population, may cause acne.

In this case report, an 18-year-old Vietnamese female with primary amenorrhea and normal female phenotype was most likely diagnosed with müllerian agenesis, highlighting its association with embryologic underdevelopment of the müllerian duct.

In this research, Sertoli cell line model ST38c demonstrated that the androgen receptor regulates hormone pathways through specific coregulators, suggesting roles for SRC-2 and HBO1 in testicular development and androgen responsiveness.

In this study, researchers concluded that sexual identity does not determine the choice of sex object, partner genders, or sexual practices among individuals born with sex differentiation disorders.

This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.

This study reports that testosterone requires conversion to DHT and estradiol for its various actions on external genitalia and bone, influencing lean mass, muscle size, strength, and body fat in hypogonadal males.

This article provides an overview of hair loss conditions and treatments, reporting no new research findings.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

Women also use 5α-reductase inhibitors, and their effects differ from men.